» Articles » PMID: 37330541

MiRNAs Signature As Potential Biomarkers for Cervical Precancerous Lesions in Human Papillomavirus Positive Women

Abstract

Biomarkers to identify women at risk of cervical cancer among those with high-risk HPV infection (hrHPV+) are needed. Deregulated expression of microRNAs (miRNAs) contributes to hrHPV-induced cervical carcinogenesis. We aimed at identifying miRNAs with the capacity to distinguish high (CIN2+) and low (≤ CIN1) grade cervical lesions. We sequenced miRNA libraries from Formalin-Fixed Paraffin-Embedded (FFPE) tissues from women with CIN2+ (n = 10) and age-matched women with ≤ CIN1 (n = 10), randomly and retrospectively selected from a trial that followed women for 24 months after a hrHPV+ test at the screening visit. Five miRNAs differentially expressed were validated by RT-qPCR in an independent set of FFPE tissues with a reviewed diagnosis of CIN2+ (n = 105) and ≤ CIN1 (n = 105). The Ingenuity Pathway Analysis (IPA) was conducted to identify mRNAs inversely correlated with the top 25 differentially expressed miRNAs. Inverse correlations with 401 unique mRNA targets were identified for fourteen of the top 25 differentially expressed miRNAs. Eleven of these miRNAs targeted 26 proteins of pathways deregulated by HPV E6 and E7 oncoproteins and two of them, miR-143-5p and miR-29a-3p, predicted CIN2+ and CIN3+ in the independent validation by RT-qPCR of FFPE tissues from hrHPV-positive women.

Citing Articles

Altered epigenetic landscape as infectious disease diagnostics.

Spurbeck R Epigenomics. 2024; 16(19-20):1269-1272.

PMID: 39440607 PMC: 11534112. DOI: 10.1080/17501911.2024.2415282.


The potential of circulating microRNAs as novel diagnostic biomarkers of COVID-19: a systematic review and meta-analysis.

Belete M, Anley D, Tsega S, Moges N, Anteneh R, Zemene M BMC Infect Dis. 2024; 24(1):1011.

PMID: 39300343 PMC: 11414062. DOI: 10.1186/s12879-024-09915-8.

References
1.
Yeo-Teh N, Ito Y, Jha S . High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int J Mol Sci. 2018; 19(6). PMC: 6032416. DOI: 10.3390/ijms19061706. View

2.
Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A . Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. Int J Cancer. 2020; 147(7):1864-1873. DOI: 10.1002/ijc.32973. View

3.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Kramer A, Green J, Pollard Jr J, Tugendreich S . Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2013; 30(4):523-30. PMC: 3928520. DOI: 10.1093/bioinformatics/btt703. View